Table 25:
Recommendations for enarodustat as an alternative to ESA for DD-CKD patients
Recommendation for use in research setting only | This recommendation is evidence informed. |
Enarodustat should not be used for DD-CKD patients, except in the context of an approved randomized controlled trial. The panel recommends conducting large head-to-head multicentric randomized controlled trials in the South Asian region on DD-CKD patients and measuring critically important outcomes (as elucidated in this guideline) such that the evidence base for enarodustat is improved. |
DD: Dialysis-Dependent, CKD: Chronic kidney disease, ESA: Eythropoiesis-stimulating agents